Pharmacoeconomics of cancer therapy

S. E. Beltz, G. C. Yee

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


Background: In 1990, annual costs of the diagnosis and treatment of cancer reached nearly $100 billion and currently constitutes approximately 10% of breath care expenditures in the United States. As new and often more expensive therapies for cancer treatment become available, the health care decision-maker must consider the cost effectiveness of the therapy. Methods: Key principles of economic analyses and the inherent differences among these analyses are reviewed. Results: While pharmacoeconomic analyses are increasingly being used in treatment decision-making, several issues relating to study design, data collection, and research methods are controversial. Conclusions: Pharmacoeconomics analyses are necessary in the current health care environment, but the assumptions used within the analyses warrant careful evaluation.

Original languageEnglish (US)
Pages (from-to)415-424
Number of pages10
JournalCancer Control
Issue number5
StatePublished - 1998

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Pharmacoeconomics of cancer therapy'. Together they form a unique fingerprint.

Cite this